Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Richard Conway RichardPAConway
3 years 1 month ago
Auroux et al report differential micro-RNA signatures in hand OA compared to controls (15 upregulated, 4 downregulated). No difference erosive vs non-erosive hand OA. May elucidate pathophys but also ?treatment target @rheumnow #ACR22 Abstr#0023 https://t.co/Kzv8WDmHRU https://t.co/4nCuTjvR6d
Richard Conway RichardPAConway
3 years 1 month ago
Gisslander et al Cluster analysis in AAV in Sweden. 5 groups. 2 PR3+ groups, younger, ENT or nerve involvement - good prognosis. 2 older MPO+ groups - lung or renal involvement - worse prognosis. @rheumnow #ACR22 Abstr#0433 https://t.co/itokBTOujS https://t.co/PG6CpZvN1a
Olga Petryna DrPetryna
3 years 1 month ago
#abst0129 #acr22 @rheumnow analysis 6 Euro studies of active RA, PsA, axSpA &secondary failure of TNFαi showed golimumab to be effective 2nd-line Rx. GLM show improvement in Dis activity, QoL& high retention( 2/3 pts on Rx after 12mo). https://t.co/6OeKwJpqQp
Richard Conway RichardPAConway
3 years 1 month ago
Kirby et al @colmkirby22 . Subclinical GCA in newly diagnosed PMR. 25 patients. 20% had LVV on US - TA in all, axillary in 1. All 5 developed clinical GCA over 1 year. @rheumnow #ACR22 Abstr#0478 https://t.co/xMMjH2XCUD https://t.co/JEtwEGTEbP
Richard Conway RichardPAConway
3 years 1 month ago
Papo et al. EGPA. Predictors of relapse: Age at diagnosis GC dependent asthma before EGPA (HR1.57), Arthralgia(HR 1.27),myocarditis(HR1.74),peripheral neuropathy(HR 1.39) MPO-ANCA(HR1.56), baseline eosinophil count @rheumnow #ACR22 Abstr#0432 https://t.co/Yq6Eomr9z0 https://t.co/8CYOYROi72
David Liew drdavidliew
3 years 1 month ago
Genicular nerve block for knee OA - exciting short-term symptomatic option, great Australian work on the Ignite stage. Looking forward to seeing more!
ABST1892 Shanahan et al @Flinders #ACR22 @RheumNow https://t.co/ssYoXj4wjg
Eric Dein ericdeinmd
3 years 1 month ago
Ab0373 #ACR22 SpA-U
@ChristianaSiero:
42 pts w/ SpA-r uveitis, 190 attacks
Uveitis more severe: smoking, axial & peripheral involvement, BASDAI>4, HLA-B27+, female, CRP elevation, h/o bilateral ocular involvement
Less severe: shorter disease evolution, nml vit D
@Rheumnow
TheDaoIndex KDAO2011
3 years 1 month ago
Important! Abst#2054 A Novel Treatment Response Measure (TRM) for SLE Clinical Trials is being developed, an international collaboration by clinical-academics, regulatory experts, pt reps, & industry. It will impact how clinical trials will be designed. #ACRbest @rheumnow #ACR22
Janet Pope Janetbirdope
3 years 1 month ago
Be careful what you look for? Serum from 32 ACPA+ Pts and 30 ACPA neg all w #rheumatoidarthritis had multiplexed Ab- screening microarray w 1600+ antibodies. Novel Abs were identified in each group vs healthy controls. What does this mean? #ACR22 abst#0256 @RheumNow @ACRheum https://t.co/mqL8kuUkxY
Olga Petryna DrPetryna
3 years 1 month ago
#ACR22 @RheumNow how do you approach treatment choices for your PsA pts on TNF inhibitors after first TNFi failure?
Robert B Chao, MD doctorRBC
3 years 1 month ago
Large Korean study on risk of infections in ankylosing spondylitis patients receiving biologics.
Infection incidence risk 26 events/1000 PY
Resp infection most common, 2nd zoster
Heart disease, high DA, DM, current bDMARD use = risk factors
Abs#0372 @RheumNow #ACR22
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#1205. Are both mRNA vaccine Pfizer or Moderna equivocal in preventing breakthrough infection in fully vaccinated patients with SARDs? @zach_wallace_md showed comparable effectiveness between the two. We can promote whichever brands to our patients @RheumNow https://t.co/yhjxNE8pr2
Eric Dein ericdeinmd
3 years 1 month ago
Ab0374 #ACR22 BASDAI during pregnancy:
50 pregnant women w/ AS vs controls
AUC for BASDAI in 1st trimester: 0.74, max value for morning stiffness severity (0.9) & duration (0.8)
In 2nd and 3rd trimester: AUC for fatigue and back pain <0.5, morning stiffness remains 0.8
@RheumNow https://t.co/ZQyB37dDxX
Eric Dein ericdeinmd
3 years 1 month ago
Happening soon in Terrace Ballroom 2
@RheumNow #acr22 https://t.co/6FMFlPxEHc
Dr. Rachel Tate uptoTate
3 years 1 month ago
Abs 0135 suggests that JAKi may successful tx for Inflammatory ocular pathology (IOP), including uveitis, epi/scleritis, & peripheral ulcerative keratitis, including after failure of cs/bDMARDs. #ACR22 @RheumNow https://t.co/9EDhtSzj1C https://t.co/0LqssF1P8H
Poster Hall